Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
As Inflation Reduction Act negotiations begin, CLL Society is ensuring CMS understands the importance of treatments for CLL patients and physicians.
Acalabrutinib, venetoclax, and obinutuzumab is a highly active, time-limited frontline therapy for patients with high-risk CLL.
The AMPLIFY trial of acalabrutinib plus venetoclax, with or without obinutuzumab, could lead to the FDA approval of the first all-oral frontline CLL therapy.
Acalabrutinib plus obinutuzumab had a 100 percent response rate at 14 months and a deep reduction of disease in the bone marrow in treatment-naive CLL.
Resistance mutations in BTK and PLCG2 are common in patients with CLL who progress on acalabrutinib, a BTK inhibitor treatment that is taken continuously.
An interim analysis of the AMPLIFY trial comparing acalabrutinib and venetoclax with or without obinutuzumab for CLL shows improvements in patient survival.
A Matching-Adjusted Indirect Comparison (MAIC) Case Study: Zanubrutinib vs. Acalabrutinib Education Activity
Acalabrutinib may be taken alone or in combination with obinutuzumab as a preferred initial (first-line) treatment, or alone as a second- or thirdline treatment.
Zanubrutinib is an excellent option for patients with CLL / SLL who are unable to tolerate acalabrutinib due to side effects.
One click to our most popular content.
